| Primary |
| Colitis Ulcerative |
34.7% |
| Crohn's Disease |
24.8% |
| Ill-defined Disorder |
9.9% |
| Product Used For Unknown Indication |
7.9% |
| Hypertension |
4.0% |
| Ileitis |
4.0% |
| Gastrointestinal Inflammation |
3.0% |
| Atypical Pneumonia |
2.0% |
| Inflammatory Bowel Disease |
2.0% |
| Influenza |
2.0% |
| Myocarditis |
2.0% |
| Ulcerative Colitis |
2.0% |
| Cytomegalovirus Infection |
1.0% |
| Hypokalaemia |
1.0% |
|
| Tubulointerstitial Nephritis |
17.6% |
| Interstitial Lung Disease |
11.8% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
5.9% |
| Intestinal Infarction |
5.9% |
| Myopericarditis |
5.9% |
| Platelet Count Decreased |
5.9% |
| Pleurisy |
5.9% |
| Testicular Germ Cell Cancer |
5.9% |
| Benign Intracranial Hypertension |
2.9% |
| Colon Cancer |
2.9% |
| Hypersensitivity |
2.9% |
| Influenza |
2.9% |
| Intestinal Diaphragm Disease |
2.9% |
| Intracranial Pressure Increased |
2.9% |
| Lung Injury |
2.9% |
| Maternal Drugs Affecting Foetus |
2.9% |
| Meningomyelocele |
2.9% |
| Myocarditis |
2.9% |
| Oedema |
2.9% |
| Organising Pneumonia |
2.9% |
|
| Secondary |
| Crohn's Disease |
27.0% |
| Product Used For Unknown Indication |
26.4% |
| Colitis Ulcerative |
17.9% |
| Lymphoproliferative Disorder |
4.1% |
| Ill-defined Disorder |
3.7% |
| Colitis |
3.5% |
| Prophylaxis |
2.2% |
| Drug Use For Unknown Indication |
2.0% |
| Foetal Exposure During Pregnancy |
2.0% |
| Gastric Disorder |
1.8% |
| Evidence Based Treatment |
1.5% |
| Inflammatory Bowel Disease |
1.3% |
| Cytomegalovirus Infection |
1.1% |
| Rheumatoid Arthritis |
1.1% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
0.7% |
| Epstein-barr Virus Infection |
0.7% |
| Hypertension |
0.7% |
| Lymphangitis |
0.7% |
| Renal Transplant |
0.7% |
| Anaemia |
0.6% |
|
| Renal Impairment |
12.3% |
| Pyrexia |
8.8% |
| Lipase Increased |
7.0% |
| Myopericarditis |
7.0% |
| Tubulointerstitial Nephritis |
7.0% |
| Pancreatitis |
5.3% |
| Pneumonia |
5.3% |
| Rash |
5.3% |
| Acute Febrile Neutrophilic Dermatosis |
3.5% |
| Adenocarcinoma |
3.5% |
| Blood Amylase Increased |
3.5% |
| Endocarditis |
3.5% |
| Enterocolitis |
3.5% |
| Eosinophilic Pneumonia |
3.5% |
| Liver Disorder |
3.5% |
| Neutropenic Sepsis |
3.5% |
| Pleurisy |
3.5% |
| Premature Baby |
3.5% |
| Renal Failure Acute |
3.5% |
| Renal Tubular Necrosis |
3.5% |
|
| Concomitant |
| Crohn's Disease |
39.3% |
| Drug Use For Unknown Indication |
16.3% |
| Product Used For Unknown Indication |
14.9% |
| Colitis Ulcerative |
11.9% |
| Hypertension |
2.4% |
| Rheumatoid Arthritis |
2.2% |
| Prophylaxis |
1.7% |
| Pain |
1.4% |
| Depression |
1.3% |
| Colitis |
1.2% |
| Anxiety |
1.0% |
| Inflammatory Bowel Disease |
1.0% |
| Vitamin Supplementation |
0.9% |
| Insomnia |
0.7% |
| Gastrooesophageal Reflux Disease |
0.7% |
| Gastric Disorder |
0.7% |
| Ankylosing Spondylitis |
0.6% |
| Blood Cholesterol Increased |
0.6% |
| Osteoporosis |
0.6% |
| Antibiotic Prophylaxis |
0.5% |
|
| Pyrexia |
13.9% |
| Incorrect Dose Administered |
13.3% |
| Vomiting |
9.9% |
| Wrong Technique In Drug Usage Process |
8.5% |
| Crohn's Disease |
6.9% |
| Weight Decreased |
6.7% |
| Injection Site Extravasation |
5.6% |
| Pneumonia |
4.5% |
| Malaise |
3.7% |
| Pain In Extremity |
3.2% |
| Infusion Related Reaction |
2.7% |
| Injection Site Irritation |
2.7% |
| Rectal Haemorrhage |
2.7% |
| Weight Increased |
2.7% |
| Sepsis |
2.4% |
| Colitis Ulcerative |
2.1% |
| Injection Site Pain |
2.1% |
| Intestinal Stenosis |
2.1% |
| Nausea |
2.1% |
| Sensation Of Heaviness |
2.1% |
|
| Interacting |
| Colitis Ulcerative |
100.0% |
|
|
